Xtacy Therapeutics Corp.
Pegasus Mercantile Inc. is an incubator, venture capital firm specializing in incubation, startup and early stage. The firm seeks to invest in the public and private sectors that focus on preventative health, wellness issues, related consumer products, biotechnology, specific areas of pain, Psychedelic, depression, mental illness health and medicine sectors. By investing in pioneering techniques … Read more
Xtacy Therapeutics Corp. (XTCYF) - Net Assets
Latest net assets as of June 2025: $-368.72K USD
Based on the latest financial reports, Xtacy Therapeutics Corp. (XTCYF) has net assets worth $-368.72K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($369.23K) and total liabilities ($737.94K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-368.72K |
| % of Total Assets | -99.86% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Xtacy Therapeutics Corp. - Net Assets Trend (2020–2024)
This chart illustrates how Xtacy Therapeutics Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Xtacy Therapeutics Corp. (2020–2024)
The table below shows the annual net assets of Xtacy Therapeutics Corp. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | $-448.20K | -64.97% |
| 2023-09-30 | $-271.68K | +39.45% |
| 2022-09-30 | $-448.66K | +13.26% |
| 2021-09-30 | $-517.22K | -98.43% |
| 2020-09-30 | $-260.65K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Xtacy Therapeutics Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 538112200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $41.86 Million | % |
| Total Equity | $-448.20K | 100.00% |
Xtacy Therapeutics Corp. Competitors by Market Cap
The table below lists competitors of Xtacy Therapeutics Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
$267.38K |
|
PetVivo Holdings Inc. Warrant
NASDAQ:PETVW
|
$267.43K |
|
First Berlin Bancorp Inc.
OTCMKTS:FTFI
|
$267.50K |
|
CLAS OHLSON -B-
BE:OHCB
|
$267.62K |
|
Sensor Technologies Corp
PINK:MOOIF
|
$267.28K |
|
Origen Resources Inc
PINK:OGGNF
|
$267.26K |
|
Protagenic Therapeutics
NASDAQ:PTIX
|
$266.65K |
|
TenX Protocols Inc.
V:TNX
|
$266.64K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Xtacy Therapeutics Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -271,681 to -448,202, a change of -176,521.
- Net loss of 546,008 reduced equity.
- Other factors increased equity by 369,487.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-546.01K | -121.82% |
| Other Changes | $369.49K | +82.44% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Xtacy Therapeutics Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-09-30 | $-0.02 | $0.02 | x |
| 2021-09-30 | $-0.02 | $0.02 | x |
| 2022-09-30 | $-0.01 | $0.02 | x |
| 2023-09-30 | $-0.03 | $0.02 | x |
| 2024-09-30 | $-0.04 | $0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Xtacy Therapeutics Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -929.93%
- • Asset Turnover: 0.14x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | -1349.72% | 25.47x | 0.00x | $-1.35 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.53 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.32 Million |
| 2023 | 0.00% | -1777.20% | 0.06x | 0.00x | $-428.74K |
| 2024 | 0.00% | -929.93% | 0.14x | 0.00x | $-501.19K |
Industry Comparison
This section compares Xtacy Therapeutics Corp.'s net assets metrics with peer companies in the Credit Services industry.
Industry Context
- Industry: Credit Services
- Average net assets among peers: $42,167,772,618
- Average return on equity (ROE) among peers: 3.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Xtacy Therapeutics Corp. (XTCYF) | $-368.72K | 0.00% | N/A | $267.38K |
| Accord Financial Corp (ACCFF) | $103.96 Million | 11.43% | 4.00x | $8.00 Million |
| Acom Co. Ltd (ACJJF) | $306.73 Billion | 3.47% | 2.77x | $799.50 Million |
| Affirm Holdings Inc (AFRM) | $3.07 Billion | 1.70% | 2.63x | $13.28 Billion |
| Federal Agricultural Mortgage Corporation (AGM) | $47.20 Million | 1.69% | 11.77x | $1.51 Billion |
| Aiful Corp (AIFLF) | $97.47 Billion | -37.44% | 4.75x | $852.52 Million |
| Jianpu Technology Inc (AIJTY) | $520.74 Million | 20.38% | 0.93x | $16.37 Million |
| AIOS Tech Inc. (AIOS) | $40.53 Million | 17.61% | 0.35x | $2.83 Million |
| Ally Financial Inc (ALLY) | $13.49 Billion | 6.88% | 11.39x | $10.34 Billion |
| Alpha Investment Inc (ALPC) | $-38.66K | 0.00% | 0.00x | $166.69 Million |
| Antalpha Platform Holding Co (ANTA) | $202.32 Million | 9.14% | 10.90x | $14.83 Million |